| Summary: | It remains unclear whether the accumulation of 2-deoxy-2-[<sup>18</sup>F]fluoro-<span style="font-variant: small-caps;">d</span>-glucose (<sup>18</sup>F-FDG) before the initiation of anti-programmed death-1 (PD-1) antibody can predict the outcome after its treatment. The aim of this study is to retrospectively examine the prognostic significance of <sup>18</sup>F-FDG uptake as a predictive marker of anti-PD-1 antibody. Eighty-five patients with previously treated non-small cell lung cancer (NSCLC) who underwent <sup>18</sup>F-FDG-positron emission tomography (PET) just before administration of nivolumab or pembrolizumab monotherapy were eligible in our study, and metabolic tumor volume (MTV), total lesion glycolysis (TLG) and the maximum of standardized under value (SUV<sub>max</sub>) on <sup>18</sup>F-FDG uptake were assessed. Objective response rate, median progression-free survival and median overall survival were 36.6%, 161 days and 716 days, respectively. The frequency of any immune-related adverse events was significantly higher in patients with low <sup>18</sup>F-FDG uptake on PET than in those with high uptake. By multivariate analysis, the tumor metabolic activity by TLG and MTV was identified as an independent prognostic factor for predicting outcome after anti-PD-1 antibody therapy, but not SUV<sub>max</sub>, predominantly in patients with adenocarcinoma. Metabolic tumor indices as TLG and MTV on <sup>18</sup>F-FDG uptake could predict the prognosis after anti-PD-1 antibodies in patients with previously treated NSCLC.
|
|---|
